These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation. Miller JM, Dahan A. Int J Pharm; 2012 Jul 01; 430(1-2):388-91. PubMed ID: 22465550 [Abstract] [Full Text] [Related]
8. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations. Sun L, Zhang B, Sun J. J Pharm Sci; 2018 Jan 01; 107(1):488-494. PubMed ID: 29031956 [Abstract] [Full Text] [Related]
9. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Miller JM, Beig A, Carr RA, Webster GK, Dahan A. Mol Pharm; 2012 Mar 05; 9(3):581-90. PubMed ID: 22280478 [Abstract] [Full Text] [Related]
10. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay. Beig A, Miller JM, Lindley D, Carr RA, Zocharski P, Agbaria R, Dahan A. J Pharm Sci; 2015 Sep 05; 104(9):2941-7. PubMed ID: 25989509 [Abstract] [Full Text] [Related]
11. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane. Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller JM. AAPS J; 2013 Apr 05; 15(2):347-53. PubMed ID: 23242514 [Abstract] [Full Text] [Related]
12. Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation. Gamsiz ED, Miller L, Thombre AG, Ahmed I, Carrier RL. Biotechnol Bioeng; 2010 Feb 01; 105(2):421-30. PubMed ID: 19725043 [Abstract] [Full Text] [Related]
13. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. Tewes F, Brillault J, Couet W, Olivier JC. J Control Release; 2008 Jul 14; 129(2):93-9. PubMed ID: 18514353 [Abstract] [Full Text] [Related]
17. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPbetaCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies. Wang S, Li D, Ito Y, Liu X, Zhang J, Wu C. J Pharm Pharmacol; 2004 Oct 14; 56(10):1251-7. PubMed ID: 15482639 [Abstract] [Full Text] [Related]
18. Modeling the effect of selected cyclodextrins on nifedipine solubility. Agatonovic-Kustrin S, Morton DW, Worthington MS, Glass BD. Curr Drug Discov Technol; 2011 Jun 14; 8(2):146-54. PubMed ID: 21091429 [Abstract] [Full Text] [Related]
19. Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole. Pacheco PA, Rodrigues LNC, Ferreira JFS, Gomes ACP, Veríssimo CJ, Louvandini H, Costa RLD, Katiki LM. Parasitol Res; 2018 Mar 14; 117(3):705-712. PubMed ID: 29327323 [Abstract] [Full Text] [Related]
20. Study of the interaction between S(--) bupivacaine and 2-hydroxypropyl-beta-cyclodextrin. Moraes CM, Abrami P, de Paula E, Braga AF, Fraceto LF. Int J Pharm; 2007 Feb 22; 331(1):99-106. PubMed ID: 17071028 [Abstract] [Full Text] [Related] Page: [Next] [New Search]